骨髓增生异常综合症
医学
细胞减少
内科学
国际预后积分系统
置信区间
骨髓
作者
Yudi Zhang,Jiajin Wu,Tiejun Qin,Zefeng Xu,Shiqiang Qu,Lijuan Pan,Bing Li,Huijun Wang,Peihong Zhang,Xin Yan,Jingye Gong,Qingyan Gao,Robert Peter Gale,Zhijian Xiao
出处
期刊:Leukemia
[Springer Nature]
日期:2022-10-12
卷期号:36 (12): 2875-2882
被引量:16
标识
DOI:10.1038/s41375-022-01718-7
摘要
Abstract We used data from 852 consecutive subjects with myelodysplastic neoplasms (MDS) diagnosed according to the 2016 (revised 4th) World Health Organization (WHO) criteria to evaluate the 2022 (5th) edition WHO classification of MDS. 30 subjects previously classified as MDS with an NPM1 mutation were re-classified as acute myeloid leukaemia (AML). 9 subjects previously classified as MDS-U were re-classified to clonal cytopenia of undetermined significance (CCUS). The remaining 813 subjects were diagnosed as: MDS-5q ( N = 11 [1%]), MDS-SF3B1 ( N = 70 [9%]), MDS-biTP53 ( N = 53 [7%]), MDS-LB ( N = 293 [36%]), MDS-h ( N = 80 [10%]), MDS-IB1 ( N = 161 [20%]), MDS-IB2 ( N = 103 [13%]) and MDS-f ( N = 42 [5%]) and MDS-biTP53 ( N = 53 [7%]). 34 of these subjects came from the 53 (64%) MDS-biTP53 previously diagnosed as MDS-EB. Median survival of subjects classified as MDS using the WHO 2022 criteria was 45 months (95% Confidence Interval [CI], 34, 56 months). Subjects re-classified as MDS-biTP53 and MDS-f had significantly briefer median survivals compared with other MDS sub-types (10 months, [8, 12 months] and 15 months [8, 23 months]). In conclusion, our analyses support the refinements made in the WHO 2022 proposal.
科研通智能强力驱动
Strongly Powered by AbleSci AI